{
  "docId": "019de075-da5f-7126-b0c8-5ad6b3fad507",
  "docSlug": "2367b4018d9bb2d1e01ea441f685753d",
  "documentTitle": "Neumora Therapeutics | IPO Presentation Deck | 32 slides",
  "authorId": "neumora-therapeutics",
  "authorName": "Neumora Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 12,
  "pageCount": 32,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 16,
  "notes": "TEAE = Treatment-Emergent Adverse Events. Data compares Navacaprant vs Placebo (n=102 each).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/12",
  "deckHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507",
  "deckJsonHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json",
  "deckAnchorHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.48,
        "x": 0.02,
        "y": 0.24
      },
      "kind": "list",
      "text": "Navacaprant was well tolerated and demonstrated lower TEAE incidence rate compared to placebo: Overall discontinuation rates were higher on placebo compared to navacaprant (29% navacaprant and 37% placebo); Incidence rates of TEAEs were 35% (navacaprant) and 44% (placebo); Discontinuation rates related to TEAEs were higher on placebo compared to navacaprant (1% navacaprant and 12% placebo). The most common (>2%) TEAEs in the navacaprant group were mild to moderate in severity. Navacaprant was not associated with common side effects of current antidepressant therapies – such as weight gain or sexual dysfunction. No evidence of suicidal behavior was identified as assessed the Columbia Suicide Severity Rating Scale",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "881bdfa3-6a89-4f16-8fb4-9fae5aa5749e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.54,
        "y": 0.28
      },
      "kind": "table",
      "text": "TEAEs Incidence (>2% in either treatment group). Placebo n=102, Navacaprant n=102. Preferred Terms: Headache 5(4.9) 5(4.9), COVID-19 3(2.9) 4(3.9), Nausea 1(1.0) 5(4.9), Diarrhea 3(2.9) 2(2.0), Upper respiratory tract infection 1(1.0) 3(2.9)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48b4a007-dd32-4ec6-9416-a81d62c0bd88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.96,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Navacaprant: Well Tolerated with Lower TEAE Incidence Rate Compared to Placebo",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "715745a1-7dd3-42d8-adde-1a4baf875ab8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "98ee2ac9-4bed-4c11-8077-c364bc15f65c",
      "evidence": "table/data: TEAEs Incidence (>2% in either treatment group). Placebo n=102, Navacaprant n=102. Preferred Terms: Headache 5(4.9) 5(4.9), COVID-19 3(2.9) 4(3.9), Nausea 1(1.0) 5(4.9), Diarrhea 3(2.9) 2(2.0), Upper respirat",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 10,
      "beatId": "d8d5c84b-60b8-4c4d-81e2-30e06c864ec8",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Evidence",
      "beatSlug": "evidence",
      "evidence": "Slides showcasing Navacaprant's efficacy and safety data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 10,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "79f06519-3b69-4341-b391-de3522d321e9",
      "evidence": "The traction slides showcasing Navacaprant's efficacy and safety data.",
      "position": 1,
      "objective": "How can Navacaprant address the unmet needs in depression and anhedonia treatment?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}